Seattle, WA (PRWEB) November 12, 2012
Quorum Review IRB is adding a 14th Board meeting to the weekly schedule of Quorum’s Institutional Review Board. The expanded calendar is effective November 1, 2012. Items to be reviewed at the Thursday meeting will need to be received by 5PM PT the prior Thursday.
In 2007, Quorum Review had two (2) Board meetings each week. Quorum has been steadily adding the number of meetings in response to client requests over the last 5 years. “This move to expand the IRB meeting schedule is a clear demonstration of Quorum’s commitment to our core value of customer service,” said Cami Gearhart, JD, Quorum’s CEO. “We are pleased to continue to offer increased service levels for our clients.”
Gearhart also notes the company will not compromise its focus on superior ethics review. “Quorum will always prioritize and preserve our core mission to protect research participants. It’s an exciting time to add an additional Board meeting, as the infrastructure is solid for the 14th meeting. To that end, we’ve also engaged new Board members in the last few months to support our increased capacity.”
Quorum’s best-in-class IRB services and support includes 14 Board meetings each week plus expedited review, 24 hour site review turnaround, 36 hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s comprehensive IRB offerings include full study review in the US and Canada, a specialized phase I team, and unique processes for post-approval and registry studies.
About Quorum Review
Quorum Review is an independent ethics review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing ethics review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human research subject protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report, and is located in Seattle, WA.